Education
About Us
Working with TipRanks
Follow Us
DaVita (DVA)
NYSE:DVA
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
2.44Last Year’s EPS
2Same Quarter Last Year
Moderate Sell
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced clear operational and financial progress—IKC clinical success and first profitable year, solid full-year adjusted OI and EPS, strong cash generation, disciplined capital returns, and constructive 2026 guidance—with persistent near-term challenges including treatment-volume pressure driven by elevated mortality, residual cyber-related losses, rising patient care costs (PCC +5.9% YoY), and payer headwinds from the expiration of enhanced premium tax credits (~$40M in 2026). Management emphasized actionable clinical initiatives and gave explicit multi-year targets, and the positive results and forward guidance slightly outweigh the headwinds.Company Guidance
IKC Clinical Outcomes and Profitability
Integrated Kidney Care (IKC) delivered superior clinical outcomes (IKC patients 35% more likely to start dialysis with permanent vascular access, costs 3x lower in first 180 days, >10% improvement in treatment adherence) and fewer hospitalizations; IKC reported its first profitable full year in 2025 (full year adjusted operating income $22 million; Q4 adjusted OI $46 million) and management expects an incremental $20 million of IKC operating income growth in 2026.
Strong Full-Year Financial Results
Full year 2025 adjusted operating income was $2.094 billion and adjusted EPS from continuing operations was $10.78; Q4 adjusted OI was $586 million and Q4 adjusted EPS was $3.40. Full year free cash flow exceeded $1.0 billion.
Ambitious 2026 Guidance
Company guided 2026 adjusted operating income to $2.085B–$2.235B (midpoint ~3.2% growth) and adjusted EPS to $13.60–$15.00 (management later cited a midpoint of $14.30, ~33% YoY increase); free cash flow guidance of $1.0B–$1.25B (midpoint $1.125B).
Revenue per Treatment Momentum and Full-Year RPT Growth
Revenue per treatment (RPT) accelerated sequentially in Q4 (up approximately $12 sequentially) and full year 2025 RPT was approximately $410, up 4.7% versus 2024.
International Segment Performance
International adjusted operating income was $21 million in Q4 and $114 million for full year 2025, driven by positive organic growth and integration of Latin America acquisitions; management expects international to contribute about 1% to enterprise adjusted OI growth in 2026.
Balance Sheet and Capital Allocation Discipline
Full year share repurchases totaled nearly 13 million shares for approximately $1.8 billion; Q4 repurchases 2.7 million shares plus 1.7 million repurchased since quarter-end. Leverage ratio at year-end was 3.26x consolidated EBITDA (midpoint of 3.0–3.5x target).
Elimination of Further Mozarc Losses and Strategic Investment
No further losses expected from Mozarc (cumulative losses recognized equal to investment), improving other income; announced ~ $200 million minority investment alongside Ares for Elara Caring, expected to contribute positively to other income and support home-based ESKD care to reduce hospitalizations and missed treatments.
Clinical Initiatives to Improve Outcomes
Management outlined targeted clinical programs (vaccination push—current ~80% vs target >90%; GLP-1 adoption/adherence; advanced dialysis technologies that may reduce mortality up to ~20%; Elara Caring partnership) intended to reduce mortality, missed treatments and support volume recovery over time.
DVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 02, 2026 | $111.19 | ― | ― |
Oct 29, 2025 | $126.56 | $118.75 | -6.17% |
Aug 05, 2025 | $140.52 | $127.81 | -9.04% |
May 12, 2025 | $144.43 | $143.98 | -0.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does DaVita (DVA) report earnings?
DaVita (DVA) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is DaVita (DVA) earnings time?
DaVita (DVA) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DVA EPS forecast?
DVA EPS forecast for the fiscal quarter 2026 (Q1) is 2.44.
